Life Sciences and Healthcare

Biopharma IPOs gone wild: Highest amount ever raised as 14 companies join public ranks

This is the first of a two-part series on “Life Sciences Connect” looking at the current robust financial climate for biopharma. Watch for a report, also via BioWorld, the daily biopharma news service from Clarivate Analytics, on the record pace of fund raising in Europe shortly. The public offerings by immuno-oncology-focused Forty Seven Inc., which […]

ASCO 2018: paradigm changers and emerging blockbusters

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis was gathered both onsite at ASCO and from Clarivate Analytics Cortellis. The American Society for Clinical Oncology […]

Pbms acquire managed care companies: what this means for providers

Healthcare spending in the United States remains exorbitant—in 2017, the U.S. spent twice as much per capita on healthcare than similar Western nations. This spending is putting stress on all stakeholders, including pharmaceutical companies, pharmacy benefit managers, payers, providers, and patients. Among all stakeholders, PBMs currently face the most pressure. Their notoriety for not passing drug […]

Regulatory considerations, strategy and best practices for choosing a quality CMO

Historically, the relationship between a sponsor and a CMO has been mostly transactional – one side manages items like regulatory filings and the other simply manufactures a specific product for a fee.  Today, however, said Bryan Coleman of the EAS Consulting Group, the market and regulatory environment require a much higher degree of collaboration and […]

Under ISP, How Will your Plan Assess an Oncology Drug’s Value for an Indication?

    if(“undefined”==typeof window.datawrapper)window.datawrapper={};window.datawrapper[“ITXPo”]={},window.datawrapper[“ITXPo”].embedDeltas={“100″:785,”200″:562,”300″:488,”400″:473,”500″:428,”700″:413,”800″:413,”900″:413,”1000”:398},window.datawrapper[“ITXPo”].iframe=document.getElementById(“datawrapper-chart-ITXPo”),window.datawrapper[“ITXPo”].iframe.style.height=window.datawrapper[“ITXPo”].embedDeltas[Math.min(1e3,Math.max(100*Math.floor(window.datawrapper[“ITXPo”].iframe.offsetWidth/100),100))]+”px”,window.addEventListener(“message”,function(a){if(“undefined”!=typeof a.data[“datawrapper-height”])for(var b in a.data[“datawrapper-height”])if(“ITXPo”==b)window.datawrapper[“ITXPo”].iframe.style.height=a.data[“datawrapper-height”][b]+”px”}); Key finding: For their indication-specific pricing (ISP) programs, 52% of surveyed MCOs identified phase II/III trial data and post-approval research such as phase IV trials as the most important resources for determining an oncology therapy’s value for a new indication. Clinical guidelines also feature prominently with 34% […]

4 ways hospitals and health systems can reduce cesarean section rates

Almost one-third of births in the United States occur via cesarean section—that’s twice the 10-15% rate the World Health Organization considers ideal. Although some of these C-sections are lifesaving, many others are performed unnecessarily due to some patients believing common myths about the procedure—such as C-sections being easier on the body than vaginal births—or providers being overly […]

FDA focuses on drug supply chain security

During the last year, the FDA has held a number of public meetings to focus on strategies and issues related to the enhanced drug distribution security provisions of the Drug Supply Chain Security Act (DSCSA). The DSCSA outlines critical steps to build an electronic, interoperable system by November 2023, to identify and trace certain prescription […]

Testing Times: The Need for Non-Invasive Diagnostics in NASH

This week marks the first International NASH Day, an initiative designed to increase both physicians’ and the general population’s awareness of nonalcoholic steatohepatitis (NASH) and to try and address the current unmet needs associated with the disease. Despite increasing focus on NASH treatment development from the pharmaceutical industry, there is still a clear unmet need […]